Niklas Zojer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Niklas Zojer has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Heinz Ludwig
Wilhelminenspital
6 shared publications- Heinz Ludwig
Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
4 shared publications H. Ludwig
Wilhelminenspital
3 shared publicationsArnold Bolomsky
Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology and Hematology, Wilhelminenhospital, Vienna, Austria
2 shared publications- Arnold Bolomsky
C/o Department of Medicine I, Center for Oncology, Hematology and Outpatient Clinic and Palliative Care, Wilhelminenspital
2 shared publications - Freda Kathryn Stevenson
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 25 January 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (3) , 547-561
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arms (n = 1154) of the AMLCG (TAD/HAM versus HAM/HAM ± G-CSF followed by TAD and maintenance) and the OSHO (intermediate-dose ara-C/mitoxantrone followed by ara-C/mitoxantrone). Median age of the 1147 eligible patients was 69 (range 60–87) years. CR/CRi status at 90 days was not significantly different between the CSA (54% (95%CI: 45–64)) and the study group arms (53% (95%CI: 47–60) and 59% (95%CI: 58–63)). The five-year event-free survival (EFS) probability (primary endpoint) was 6.2% (95%CI: 2.7–14.0) in the CSA, 7.6% (95%CI: 4.5–12.8) in study group A and 11.1% (95%CI: 9.0–13.7) in B. The 5-year OS was 17.2% (95%CI: 11.0–26.9), 17.0% (95%CI: 2.0–23.9), and 19.5% (95%CI: 16.7–22.8) in CSA, study group A and B, respectively. Neither study group differed significantly from the CSA regarding EFS, OS, or relapse-free survival. In multivariate analyses, allocation to the treatment strategy was not significantly associated with the time-to-event endpoints. The evaluation of more intensive treatment strategies did not show clinically relevant outcome differences when compared to CSA.
- 25 January 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (3) , 547-561
Open AccessDifferent treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arms (n = 1154) of the AMLCG (TAD/HAM versus HAM/HAM ± G-CSF followed by TAD and maintenance) and the OSHO (intermediate-dose ara-C/mitoxantrone followed by ara-C/mitoxantrone). Median age of the 1147 eligible patients was 69 (range 60–87) years. CR/CRi status at 90 days was not significantly different between the CSA (54% (95%CI: 45–64)) and the study group arms (53% (95%CI: 47–60) and 59% (95%CI: 58–63)). The five-year event-free survival (EFS) probability (primary endpoint) was 6.2% (95%CI: 2.7–14.0) in the CSA, 7.6% (95%CI: 4.5–12.8) in study group A and 11.1% (95%CI: 9.0–13.7) in B. The 5-year OS was 17.2% (95%CI: 11.0–26.9), 17.0% (95%CI: 2.0–23.9), and 19.5% (95%CI: 16.7–22.8) in CSA, study group A and B, respectively. Neither study group differed significantly from the CSA regarding EFS, OS, or relapse-free survival. In multivariate analyses, allocation to the treatment strategy was not significantly associated with the time-to-event endpoints. The evaluation of more intensive treatment strategies did not show clinically relevant outcome differences when compared to CSA.
- 19 June 2017
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 10 (2) , 49
Notes from California – experts review the ASH meeting 2016 in San Diego
- 19 June 2017
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 10 (2) , 49
Notes from California – experts review the ASH meeting 2016 in San Diego
- 31 January 2017
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 10 (1) , 13-17
Milestones in myeloma
- 31 January 2017
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 10 (1) , 13-17
Milestones in myeloma
- 19 September 2016
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (3) , 127-130
Focus on multiple myeloma at ASH 2015
- 19 September 2016
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (3) , 127-130
Focus on multiple myeloma at ASH 2015
- 14 September 2016
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (3) , 107-108
ASH 2015—insights and outlooks
- 14 September 2016
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (3) , 107-108
ASH 2015—insights and outlooks
- Open Access
- 2 March 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-13
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
The polycomb complex protein BMI-1 (BMI-1) is a putative oncogene reported to be overexpressed in multiple myeloma (MM). Silencing of BMI-1 was shown to impair the growth and survival of MM cells. However, therapeutic agents specifically targeting BMI-1 were not available so far. Here, we investigated PTC-209, a novel small molecule inhibitor of BMI-1, for its activity in MM. BMI-1 expression was analysed in human MM cell lines and primary MM cells by using publically available gene expression profiling (GEP) data. The anti-MM activity of PTC-209 was investigated by viability testing, cell cycle analysis, annexin V and 7-AAD staining, quantification of cleaved poly(ADP-ribose) polymerase (PARP), JC-1 as well as colony formation assays. Deregulation of central myeloma growth and survival genes was studied by quantitative PCR and flow cytometry, respectively. In addition, the impact of PTC-209 on in vitro osteoclast, osteoblast and tube formation was analysed. We confirmed overexpression of BMI-1 in MM patients by using publically available GEP datasets. Of note, BMI-1 expression was further increased at relapse which translated into significantly shorter overall survival in relapsed/refractory patients treated with bortezomib or dexamethasone. Treatment with PTC-209 significantly decreased viable cell numbers in human MM cell lines, induced a G1 cell cycle arrest, promoted apoptosis and demonstrated synergistic activity with pomalidomide and carfilzomib. The anti-MM activity of PTC-209 was accompanied by a significant decrease of cyclin D1 (CCND1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expression as well as upregulation of cyclin-dependent kinase inhibitor 1A (CDKN1A) and cyclin-dependent kinase inhibitor 1B (CDKN1B). We also observed upregulation of NOXA (up to 3.6 ± 1.2-fold induction, P = 0.009) and subsequent downregulation of myeloid cell leukemia 1 (MCL-1) protein levels, which likely mediates the apoptotic effects of PTC-209. Importantly, the anti-MM activity was upheld in the presence of stromal support or myeloma growth factors insulin-like growth factor 1 (IGF-1) and interleukin 6 (IL-6). In the MM microenvironment, PTC-209 impaired tube formation, impaired osteoclast development and decreased osteoblast formation in a dose-dependent manner (P < 0.01 at 1 μM, respectively). The latter might be attributed to an induction of DKK1 and was reversed by concurrent anti-DKK1 antibody treatment. We confirmed overexpression of BMI-1 in MM highlighting its role as an attractive drug target and reveal therapeutic targeting of BMI-1 by PTC-209 as a promising novel therapeutic intervention for MM.
- 2 March 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-13
Open AccessTargeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
The polycomb complex protein BMI-1 (BMI-1) is a putative oncogene reported to be overexpressed in multiple myeloma (MM). Silencing of BMI-1 was shown to impair the growth and survival of MM cells. However, therapeutic agents specifically targeting BMI-1 were not available so far. Here, we investigated PTC-209, a novel small molecule inhibitor of BMI-1, for its activity in MM. BMI-1 expression was analysed in human MM cell lines and primary MM cells by using publically available gene expression profiling (GEP) data. The anti-MM activity of PTC-209 was investigated by viability testing, cell cycle analysis, annexin V and 7-AAD staining, quantification of cleaved poly(ADP-ribose) polymerase (PARP), JC-1 as well as colony formation assays. Deregulation of central myeloma growth and survival genes was studied by quantitative PCR and flow cytometry, respectively. In addition, the impact of PTC-209 on in vitro osteoclast, osteoblast and tube formation was analysed. We confirmed overexpression of BMI-1 in MM patients by using publically available GEP datasets. Of note, BMI-1 expression was further increased at relapse which translated into significantly shorter overall survival in relapsed/refractory patients treated with bortezomib or dexamethasone. Treatment with PTC-209 significantly decreased viable cell numbers in human MM cell lines, induced a G1 cell cycle arrest, promoted apoptosis and demonstrated synergistic activity with pomalidomide and carfilzomib. The anti-MM activity of PTC-209 was accompanied by a significant decrease of cyclin D1 (CCND1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC) expression as well as upregulation of cyclin-dependent kinase inhibitor 1A (CDKN1A) and cyclin-dependent kinase inhibitor 1B (CDKN1B). We also observed upregulation of NOXA (up to 3.6 ± 1.2-fold induction, P = 0.009) and subsequent downregulation of myeloid cell leukemia 1 (MCL-1) protein levels, which likely mediates the apoptotic effects of PTC-209. Importantly, the anti-MM activity was upheld in the presence of stromal support or myeloma growth factors insulin-like growth factor 1 (IGF-1) and interleukin 6 (IL-6). In the MM microenvironment, PTC-209 impaired tube formation, impaired osteoclast development and decreased osteoblast formation in a dose-dependent manner (P < 0.01 at 1 μM, respectively). The latter might be attributed to an induction of DKK1 and was reversed by concurrent anti-DKK1 antibody treatment. We confirmed overexpression of BMI-1 in MM highlighting its role as an attractive drug target and reveal therapeutic targeting of BMI-1 by PTC-209 as a promising novel therapeutic intervention for MM.
- 11 November 2015
- Published by Springer Nature in Wiener klinisches Magazin
- Vol. 18 (6) , 218-223
Autologe Stammzelltransplantation bei Myelompatienten
- 11 November 2015
- Published by Springer Nature in Wiener klinisches Magazin
- Vol. 18 (6) , 218-223
Autologe Stammzelltransplantation bei Myelompatienten
- 10 March 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 8 (1) , 11-15
Tailoring treatment in myeloma: are there clues from biology?
- 10 March 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 8 (1) , 11-15
Tailoring treatment in myeloma: are there clues from biology?
- Open Access
- 10 March 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 8 (1) , 1-2
Multiple myeloma: the biology, the clinic, and the future
- 10 March 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 8 (1) , 1-2
Open AccessMultiple myeloma: the biology, the clinic, and the future